Dianthus Therapeutics is developing novel Complement therapeutics to improve the quality of life of patients with autoimmune diseases. The Complement system is part of the innate immune response that can get activated in autoimmune diseases. Dianthus is designing selective monoclonal antibodies that target components of the Complement system to reduce their activity. The antibodies are modified to have a longer half-life, thus enabling therapeutics reduced dose levels and frequency. Dianthus’ pipeline is in preclinical stages, with the most advanced, DNTH103, targeting active Complement C1s. DNTH103 is selective for the active, not inactive, C1s which sets it apart from current antibody therapies and could offer a more convenient subcutaneous therapy for patients.